Latest News

First Patient Enrolled in US Study of Novate’s Sentry IVC Filter.

Galway, Ireland. 22 September 2014 – Seroba Kernel investee company, Novate Medical, announced today that Souheil Saddekni MD, Professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham has enrolled the first patient in the SENTRY IDE Study. The SENTRY study is a prospective, single-arm, multi-centre study designed to evaluate the safety and...


Veryan Presents Two-Year Results from Randomised Controlled Study of BioMimics 3D® Stent at New Cardiovascular Horizons Conference.

New Orleans, 30th May 2014 – Seroba Kernel investee company, Veryan, presented Full two-year data from the Mimics study at the 15th Annual New Cardiovascular Horizons (NCVH) Conference in New Orleans. The data confirmed that BioMimics 3D™ provides a significant improvement in long-term patency compared to a straight nitinol control stent in patients undergoing femoropopliteal...


Covagen Initiates Phase Ib/IIa Study of Bispecific anti-TNF/IL-17A FynomAb COVA322.

ZURICH-SCHLIEREN, Switzerland, May 5, 2014 – Seroba Kernel investee company, Covagen, today announced it has initiated a Phase Ib/IIa study with COVA322, a bispecific TNF/IL-17A inhibitor. COVA322 is Covagen's lead bispecific FynomAb developed for treatment of patients with rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. The trial will enroll 39...


< back to home page